Profile
ATNX ZTS TAK HLN TEVA VTRS
Company Name Athenex, Inc. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $2.33M $79.77B $43.94B $43.92B $18.86B $15.76B
Employees 0.27K 14.10K 49.28K 25.41K 37.00K 32.00K
CEO Dr. Yiu-Nam Lau F.R.C.P., M.B.B.S., M.D., Ph.D. Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Mr. Scott Andrew Smith Ph.D.
Ratings
ATNX ZTS TAK HLN TEVA VTRS
Quant Rating Score 3 3 3 3 1 3
Quant Rating Neutral Neutral Neutral Neutral Strong Sell Neutral
Trading
ATNX ZTS TAK HLN TEVA VTRS
Last Close $0.2031 $176.81 $13.86 $9.67 $16.65 $13.2
High 52 $0.2 $199.94 $15.08 $10.69 $18.96 $13.53
Low 52 $0.2 $145.54 $12.6 $8.01 $10.44 $10.05
Price vs. 52 Week High 1.55 % -11.57 % -8.09 % -9.54 % -12.18 % -2.44 %
Price vs. 52 Week Low 1.55 % 21.49 % 10 % 20.72 % 59.48 % 31.34 %
Total Return
ATNX ZTS TAK HLN TEVA VTRS
1 Month Return 0 % -2.82 % -0.72 % -0.62 % -9.76 % 13.6 %
3 Month Return 0 % -3.68 % -7.1 % -4.82 % -10.1 % 11.02 %
6 Month Return 0 % 2.58 % 3.74 % 14.17 % -1.94 % 24.76 %
9 Month Return 0 % -7.34 % -4.81 % 14.44 % 23.33 % 4.85 %
YTD Return 0 % -10.42 % -2.87 % 17.5 % 59.48 % 21.88 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ATNX ZTS TAK HLN TEVA VTRS
Dividend Yield Percentage (TTM) - 0.98 % 4.6 % 1.64 % - 3.64 %
Dividend Paid and Capex Coverage Ration (TTM) -36.41 % 2.1 % 1.34 % - 5.06 % 2.39 %
Dividend Per Share (TTM) - 1.73 % 192 % 0.06 % - 0.48 %
Payout Ratio (TTM) - 31.44 % 101.62 % - - -65.15 %
Growth
ATNX ZTS TAK HLN TEVA VTRS
Asset Growth -23.7 % -4.28 % 8.25 % -2.18 % -1.2 % -4.67 %
Gross Profit Growth -29.31 % 3.7 % 1.76 % 5.84 % 9.65 % -0.9 %
Revenue Growth -14.44 % 5.74 % 5.87 % 4.09 % 6.17 % -5.14 %
Revenue 3 Year -42.5 % 31.98 % 31.78 % 13.9 % -6.91 % -35.32 %
Revenue 5 Year 20.28 % 53.64 % 147.38 % 32.87 % -23.33 % -41.73 %
Revenue 10 Year 162.08 % 103.1 % 151.81 % 32.87 % -40.82 % -26.57 %
EBIT Growth 39.17 % 6.27 % -56.36 % 9.37 % -84.52 % -52.55 %
Net Income Growth 49.06 % 10.88 % -54.56 % -1.04 % 76.24 % -97.37 %
Net Income 3 Yeari Growth Per Share 55.37 % 47.55 % -62.13 % -8.67 % 86.29 % 104.09 %
Net Income 5 Yeari Growth Per Share 66.42 % 71.94 % 60.64 % 59.66 % 76.28 % -93.3 %
Net Income 10 Yeari Growth Per Share 30.48 % 404.24 % 34.95 % 59.66 % -133.42 % -97.12 %
Operating Income Growth 39.17 % 6.27 % -56.36 % 9.37 % -84.52 % -52.55 %
Operating Cash Flow Growth (CFG) 47.31 % 23.06 % -26.69 % 1.79 % -13.96 % -5.18 %
Operating 3 Year CFG 56.43 % 14.12 % -29.96 % 48.8 % 10.09 % 13.84 %
Operating 5 Year CFG 59.04 % 37.69 % 165.35 % 166.36 % -48.98 % -48.37 %
Operating 10 Year CFG 21.02 % 274.61 % 382.49 % 166.36 % -67.94 % -16.8 %
EPS Growth 59.53 % 12.64 % -55.38 % - 76.42 % -97.33 %
EPS Diluted Growth 59.53 % 12.92 % -54.86 % - 76.42 % -97.35 %
Book Value Per Share 100 % 15.25 % 12.4 % 1.35 % -7.25 % -1.92 %
Share Holder 3 Year Equity Growth Per Share -101.96 % 36.7 % 38.97 % -36.6 % -26.74 % -55.34 %
Share Holder 5 Year Equity Growth Per Share -103.22 % 139.55 % 71.52 % -39.41 % -53.44 % -27.35 %
Share Holder 10 Year Equity Growth Per Share -102.37 % 476.36 % 194.11 % -39.41 % -74.76 % 128.81 %
Dividend Per Share Growth - 15.15 % 0.92 % -85.58 % - -0.06 %
Dividend 3 Year Growth Per Share - 87.76 % 0.17 % -83.69 % - -
Dividend 5 Year Growth Per Share - 198.29 % 144.45 % -66.42 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % 101.87 % -66.42 % -100 % -
Debt Growth -71.82 % -16.5 % 24.67 % -9.43 % -6.53 % -4.64 %
Free Cash Flow Growth 49.6 % 22.25 % -31.4 % 1.67 % -19.19 % -7.35 %
Updated On 31 Dec 2022 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023 31 Dec 2023
Profitability
ATNX ZTS TAK HLN TEVA VTRS
Gross Profit Margin TTM 25.97 % 68.87 % 55.23 % 60.68 % 49.87 % 40.26 %
Return on Assets TTM -48.5 % 16.93 % 1.99 % 3.26 % -2.38 % -1.97 %
Return on Equity TTM 21.51 % 47.99 % 4.04 % 6.54 % -14.58 % -4.43 %
Return on Capital Employed TTM -78.42 % 26.36 % 4.18 % 7.22 % 7.66 % -0.71 %
Net Income Per EBT TTM 100.35 % 79.65 % 108.74 % 65.38 % 175.89 % 92.81 %
EBT Per Ebit TTM 141.03 % 91.46 % 52.35 % 82.95 % -26.34 % 359.67 %
EBIT Per Revenue TTM -68.02 % 36.45 % 11.21 % 17.82 % 12.76 % -1.76 %
Cash Flow To Debt Ratio TTM -177.1 % 44.8 % 16.58 % - 13 % 13.05 %
Receivables Turnover TTM 3.69 6.49 6.3 5.27 4.85 3.81
Payables Turnover TTM 2.26 7.05 4.92 1.23 3.55 7.23
Inventory Turnover TTM 1.78 1.18 1.69 3.03 2.13 2.2
Fixed Asset Turnover TTM 1701.49 % 259.93 % 240.84 % 604.62 % 278.05 % 561.67 %
Asset Turnover TTM 50.39 % 63.75 % 31.2 % 33.71 % 40.19 % 33.6 %
Operating Cash Flow Per Share TTM -11.47 6.5 528.88 - 2.18 1.93
Free Cash Flow Per Share TTM -11.78 5.1 321.24 - 1.75 1.6
Cash Per Share TTM 560.93 % 378.45 % 57241.03 % 5.72 % 292.94 % 171.57 %
Operating Cash Flow Sales Ratio TTM -72.96 % 32.18 % 18.42 % - 14.71 % 15.29 %
Free Cash Flow Operating Cash Flow Ratio TTM 102.75 % 78.37 % 60.74 % - 80.23 % 83.19 %
Cash Flow Coverage Ratios TTM -177.1 % 44.8 % 16.58 % - 13 % 13.05 %
Price To Free Cash Flows Ratio TTM -0.03 34.56 13.02 - 9.53 8.24
Price To Operating Cash Flows Ratio TTM -0.02 27.19 7.9 - 7.64 6.85
Price Cash Flow Ratio TTM -0.02 27.19 7.9 - 7.64 6.85
Income Statement (TTM)
ATNX ZTS TAK HLN TEVA VTRS
Revenue $0.1B $8.54B $4263.76B $11.3B $15.85B $15.43B
Gross Profit $0.03B $5.83B $2832.26B $6.96B $7.65B $6.44B
Gross Profit Ratio 25.97% 68.28% 66.43% 61.59% 48.25% 41.74%
EBITDA $-0.07B $3.69B $900.33B $2.35B $1.57B $3.46B
Net Income $-0.1B $2.34B $144.07B $1.05B $-0.56B $0.05B
EPS Diluted -15.13 5.07 91.16 0.11 -0.5 0.05
Balance Sheet (MRQ)
ATNX ZTS TAK HLN TEVA VTRS
Long Term Debt $0B $6.75B $5029.93B $8.8B $18.48B $16.35B
Total Liabilities $0.2B $9.3B $7834.79B $17.33B $35.35B $27.22B
Total Equity $-0.02B $4.99B $7274.01B $16.73B $8.13B $20.47B
Total Investments $0B $0.02B $445.7B $0.07B $0.01B $1.33B
Total Debt $0.04B $6.76B $5463.39B $9.46B $20.15B $18.37B
Total Assets $0.2B $14.29B $15108.79B $34.06B $43.48B $47.69B
Cash Flow Statement (TTM)
ATNX ZTS TAK HLN TEVA VTRS
Net Income $-0.1B $2.34B $144.07B $1.11B $-0.62B $0.05B
Inventory $-0.02B $-0.36B $-115.74B $-0.13B $0B $-0.61B
Dividends Paid $0B $-0.69B $-287.19B $-0.39B $0B $-0.58B
Operating Cash Flow $-0.08B $2.35B $716.34B $2.1B $1.37B $2.8B
Capital Expenditure $-0B $-0.73B $-480.73B $-0.34B $-0.53B $-0.47B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.41
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.7
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 11.61
ALVOW Alvotech 2.58
AMPH Amphastar Pharmaceuticals, Inc. 44.92
AMRX Amneal Pharmaceuticals, Inc. 8.53
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 56.87
AQST Aquestive Therapeutics, Inc. 4.39
ASRT Assertio Holdings, Inc. 0.9989
AVDL Avadel Pharmaceuticals plc 9.94
AYTU Aytu BioPharma, Inc. 1.5854
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to ATNX
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0 140
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00001 133.37
BIB ProShares Ultra Nasdaq Biotechnology 0 58.05
IEIH iShares Evolved U.S. Innovative Healthcare ETF 0 34.1348
DFAU Dimensional US Core Equity Market ETF 0 42.12
IBBQ Invesco Nasdaq Biotechnology ETF 0 22.91
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0 6.71
VEXPX Vanguard Explorer Fd 0 131.75
JKK iShares Morningstar Small-Cap Growth ETF 0.01 307.42
JKJ iShares Morningstar Small-Cap ETF 0 231.193
Unlock